Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2629-3277
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy ; day:19 ; month:5 ; year:2022 ; pages:1-21
Stem cell reviews and reports ; (19.5.2022), 1-21
- Creator
-
Siemionow, Maria
Langa, Paulina
Brodowska, Sonia
Kozlowska, Katarzyna
Zalants, Kristina
Budzynska, Katarzyna
Heydemann, Ahlke
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12015-022-10384-2
- URN
-
urn:nbn:de:101:1-2022072123155907795346
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Siemionow, Maria
- Langa, Paulina
- Brodowska, Sonia
- Kozlowska, Katarzyna
- Zalants, Kristina
- Budzynska, Katarzyna
- Heydemann, Ahlke
- SpringerLink (Online service)
Other Objects (12)
Correction: Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Trans‐generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review
Correction: Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Trans‐generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review
Correction: Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Trans‐generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy